{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 20 February 2007\line \line {\b Roche 
and GSK agree on two transactions} \par}{\pard\f0\li440\ri0\sl360\fs22 - Roche to 
out-license orlistat non-prescription rights to GSK beyond US\par}{\pard\f0\li440\ri0\sl360\fs22 - Roche 
and GSK to settle all arbitration procedures related to carvedilol\par}\line {\pard\f0\li0\ri0\sa360\sl360\fs22 \line Roche 
has granted GlaxoSmithKline Consumer Healthcare an exclusive license for the non-prescription rights 
to its anti-obesity medicine orlistat in non-US countries excluding Japan. Roche retains all worldwide 
rights for the prescription version of orlistat and continues to market it under the brand name Xenical 
120 mg. The transaction follows the agreement in July 2004 where Roche already out-licensed the US non-prescription 
rights to orlistat 60 mg to GSK. Roche will receive an upfront payment. The financial terms are not 
disclosed. Roche will support GSK with supply during an initial period.\line \line "Roche 
has gained a top-tier partner in pursuing a successful OTC brand based on our prescription medicine 
Xenical," said William M. Burns, CEO Roche Pharma. "Given the strong expertise in the consumer 
health business, we believe that GSK will maximize the potential of this effective weight loss drug 
in the non-prescription area."\line \line In a separate transaction both companies 
agreed to settle all arbitration procedures between the two companies relating to the licensing and 
co-marketing of carvedilol. As part of this settlement agreement, Roche will make an undisclosed payment 
to GSK, for which sufficient financial provisions have already been made.\line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of 
innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, 
the Group contributes on a broad range of fronts to improving people\u8217?s health and quality of life. Roche 
is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a 
market leader in virology. In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss 
francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 
75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, 
including majority ownership interests in Genentech and Chugai. Additional information about the Roche 
Group is available on the Internet at www.roche.com (http://www.roche.com).\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used or mentioned in this release are protected by law.\par}\line \line \line Additional 
information\line - GlaxoSmithKline (http://www.gsk.com)\par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}